Navigation Links
Insmed to Host 2012 First Quarter Earnings Conference Call
Date:4/24/2012

timing of and costs associated with pre-clinical studies and clinical trials, the development of our products, and the business strategies, plans and objectives of management, constitute forward-looking statements which involve risks and uncertainties that could cause actual results to differ materially from those anticipated by the forward-looking statements.  Our results may be affected by such factors as the receipt and timing of FDA and other regulatory reviews and approvals, if at all, competitive developments affecting our product development, delays in product development or clinical trials, and patent disputes involving currently developing products.  The risks and uncertainties include, without limitation, we may experience unexpected regulatory actions, delays or requests, our future clinical trials may not be successful, we may be unsuccessful in developing our product candidates or receiving necessary regulatory approvals, we may experience delays in our product development or clinical trials, our product candidates may not prove to be commercially successful, our expenses may be higher than anticipated and other risks and challenges detailed in our filings with the U.S. Securities and Exchange Commission, including our Annual Report on Form 10-K for the year ended December 31, 2011. Investors are cautioned not to place undue reliance on any forward-looking statements which speak only as of the date of this release.  We undertake no obligation to publicly release the results of any revisions to these forward-looking statements that may be made to reflect events or circumstances that occur after the date of this release or to reflect the occurrence of unanticipated events.

Investor Relations Contact:
Brian Ritchie – FTI Consulting
212-850-5683
brian.ritchie@fticonsulting.com

Media Contact:
Irma Gomez-Dib – FTI Consulting
212-850-576
'/>"/>

SOURCE Insmed Incorporated
Copyright©2010 PR Newswire.
All rights reserved

Page: 1 2 3

Related medicine technology :

1. Insmed to Host Fourth Quarter and 2011 Year-End Earnings Conference Call
2. Insmed to Present at Lazard Capital Markets 8th Annual Healthcare Conference
3. Insmed Incorporated Provides Regulatory Update on ARIKACE® in Non-Tuberculous Mycobacteria Indication
4. Insmed Incorporated Provides Regulatory Update
5. Insmed to Present at Sixth Annual JMP Securities Healthcare Conference
6. Insmed Announces Financial Results for Second Quarter and Six-Months Ended June 30, 2011
7. Insmeds ARIKACE® Demonstrates Sustained Benefit Through Six Cycles of Treatment for Cystic Fibrosis Patients With Pseudomonas Lung Infections
8. Insmed Announces First Quarter 2011 Financial Results
9. Insmed to Host 2011 First Quarter Earnings Conference Call
10. Insmed Announces European Medicines Agency Acceptance of Its Pediatric Investigation Plan for ARIKACE™ in the Cystic Fibrosis Pseudomonas Indication
11. One-for-10 Reverse Stock Split of Insmed Common Stock Becomes Effective
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:12/24/2014)... , Dec. 24, 2014  Novastem, a leader ... first patient in its study for ischemic stroke ... Stroke Association, ischemic strokes account for 87 percent ... qualified patients in the study, entitled "Internal Research ... Allogeneic Mesenchymal Stem Cells and Intrathecal Administration of ...
(Date:12/24/2014)... Dec. 24, 2014 /PRNewswire/  -- Tianyin Pharmaceutical Inc. ... company that specializes in the patented biopharmaceutical, modernized ... pharmaceutical ingredients (API) released unaudited preliminary financial results ... Fiscal Year 2015 Ended September 30, ... million compared with $14.7 million in 1Q14 with ...
(Date:12/24/2014)... , Dec. 24, 2014  The International Trade Commission (ITC) ... (RMD) against BMC Medical. In a notice issued on December ... that ResMed,s patent on its humidifier was invalid. ... "monumental win". "We are very excited with the ITC,s decision ... that we have taken since the very beginning on the ...
Breaking Medicine Technology:Novastem Treats First Patient Using Stemedica's Mesenchymal and Neural Stem Cell Combination Therapy for Ischemic Stroke 2Novastem Treats First Patient Using Stemedica's Mesenchymal and Neural Stem Cell Combination Therapy for Ischemic Stroke 3Novastem Treats First Patient Using Stemedica's Mesenchymal and Neural Stem Cell Combination Therapy for Ischemic Stroke 4TPI Presents Unaudited Preliminary First Quarter Fiscal Year 2015 Financial Results 2TPI Presents Unaudited Preliminary First Quarter Fiscal Year 2015 Financial Results 3TPI Presents Unaudited Preliminary First Quarter Fiscal Year 2015 Financial Results 4TPI Presents Unaudited Preliminary First Quarter Fiscal Year 2015 Financial Results 5TPI Presents Unaudited Preliminary First Quarter Fiscal Year 2015 Financial Results 6TPI Presents Unaudited Preliminary First Quarter Fiscal Year 2015 Financial Results 7TPI Presents Unaudited Preliminary First Quarter Fiscal Year 2015 Financial Results 8TPI Presents Unaudited Preliminary First Quarter Fiscal Year 2015 Financial Results 9TPI Presents Unaudited Preliminary First Quarter Fiscal Year 2015 Financial Results 10TPI Presents Unaudited Preliminary First Quarter Fiscal Year 2015 Financial Results 11TPI Presents Unaudited Preliminary First Quarter Fiscal Year 2015 Financial Results 12ITC Final Decision Goes Against ResMed (RMD) Monumental Win for 3B/BMC 2
... , WILMINGTON, Del., Dec. 8 ... enrolled in the company,s Medicare Part D prescription savings program ... program. , (Logo: http://www.newscom.com/cgi-bin/prnh/20091027/PH99766LOGO ) , ... physician,s offices under the changes to the AZ&Me(TM) Prescription Savings ...
... , WALTHAM, ... leading research and advisory firms for pharmaceutical and healthcare issues, ... levofloxacin, moxifloxacin and piperacillin/tazobactam -- will be the primary factors ... the community-acquired pneumonia drug market though 2018. , The new ...
Cached Medicine Technology:AstraZeneca Medicare Part D Patient Assistance Program No Longer Requires Co-Pays 2Patent Expiries of Blockbuster Antibiotics Will Fuel a Decline of More Than 15 Percent in the Community-Acquired Pneumonia Drug Market 2
(Date:12/26/2014)... 2014 Parker & Sons, Inc. ... in heating, cooling and plumbing contractor services throughout ... services in 2014 with regard to air-conditioning systems. ... is known for its incredibly hot summers. Working ... intricacies and details of a wide variety of ...
(Date:12/25/2014)... 2014 The click strand ... strength and durability. Today, the business announces a ... valid until Jan. 30, 2015. , Click strand ... hardwood. BambooFlooringChina.com is a well-known brand in the ... to find a reliable bamboo flooring supplier. , ...
(Date:12/25/2014)... 2014 Product liability lawsuits filed in ... ( http://www.consumerinjurylawyers.com/DePuy/ ) continue to move forward in federal ... issued in the U.S. District Court, Northern District of ... open conference on January 7, 2015, at the Paul ... West Palm Beach, Florida. The Conference is scheduled to ...
(Date:12/25/2014)... Recently, Dylan Queen, a famous online company supplying ... of discounted prom dresses, most of which are priced ... the company, the promotion is valid until Jan. 22, ... the UK market. , The prom dresses in this ... styles: A-line strapless, empire strapless chiffon, one shoulder, floor-length, ...
(Date:12/25/2014)... sells many bamboo products and the business is famous ... announces big discounts on its bamboo mats , which ... the world’s leader in bamboo flooring. According to the ... 2015. , The bamboo mats are made from well-treated ... the bamboo strips for the mats are boiled and ...
Breaking Medicine News(10 mins):Health News:Parker & Sons Announces Record Demand For 24 Hour Emergency Services In 2014 With Regard To Air-Conditioning Systems 2Health News:Parker & Sons Announces Record Demand For 24 Hour Emergency Services In 2014 With Regard To Air-Conditioning Systems 3Health News:BambooFlooringChina.com: click strand woven bamboo flooring promotion valid until Jan. 30, 2015. 2Health News:Federal Court Overseeing DePuy ASR Hip Lawsuit Set to Convene Conference in January, Bernstein Liebhard LLP Reports 2Health News:Federal Court Overseeing DePuy ASR Hip Lawsuit Set to Convene Conference in January, Bernstein Liebhard LLP Reports 3Health News:Dylan Queen: Cheap Prom Dresses for the UK Market 2Health News:Various Styles of Bamboo Mats in Many Colors from BambooFlooringChina.com 2
... KidsHealth.org ... App” developer challenge to inspire mobile users in the fight against obesity. Joins forces ... , ... (Vocus) -- KidsHealth.org , the most-visited site on the Web for information ...
... has awarded $10.24 million to Fred Hutchinson Cancer Research ... understand and prevent breast cancer disparities in Hispanic women. ... to receive funding as part of the NIH Centers ... launching a major new effort to understand and address ...
... Faculty Scholars programs have awarded $800,000 in combined new ... Both programs funded by the John A. Hartford ... are components of the nationwide Geriatric Social Work ... workers in order to improve the health and well being of ...
... Pre-Auction ... ... organization founded to accelerate research in Lou Gehrig,s disease, launched its “Art, Life, Spring” charity ... The auction will be open for bidding online from May 3, 2010 through June ...
... Mass. -- Our DNA is under constant siege from a ... of cells to repair that damage has broad health implications, ... used to study DNA damage are quite limited, but MIT ... analysis that promises to make an impact on human health. ...
... Lung researchers at Johns Hopkins have identified a possible ... disease marked by tiny clumps of inflammatory cells that ... lymph nodes, skin and almost all major organs in ... cause has been a persistent mystery for nearly a ...
Cached Medicine News:Health News:KidsHealth Challenges App Developers to Battle Obesity 2Health News:KidsHealth Challenges App Developers to Battle Obesity 3Health News:Hutchinson Center receives $10.24 million from NIH for Latina breast cancer research 2Health News:Hutchinson Center receives $10.24 million from NIH for Latina breast cancer research 3Health News:Hutchinson Center receives $10.24 million from NIH for Latina breast cancer research 4Health News:Hutchinson Center receives $10.24 million from NIH for Latina breast cancer research 5Health News:Hartford grants increase support for geriatric social work training 2Health News:Hartford grants increase support for geriatric social work training 3Health News:Prize4Life Launches “Art, Life, Spring” Online Art Auction to Raise Funds for Lou Gehrig's Disease Research 2Health News:Prize4Life Launches “Art, Life, Spring” Online Art Auction to Raise Funds for Lou Gehrig's Disease Research 3Health News:Rapid analysis of DNA damage now possible 2Health News:A century-old puzzle comes together: Scientists ID potential protein trigger in lung disease sarcoidosis 2Health News:A century-old puzzle comes together: Scientists ID potential protein trigger in lung disease sarcoidosis 3
... reference laboratory and a worldwide leader in ... an extensive test menu of highly complex ... anatomic pathology. Owned by the University of ... half of the nation's university teaching hospitals ...
... a national reference laboratory and a worldwide ... ARUP offers an extensive test menu of ... clinical and anatomic pathology. Owned by the ... more than half of the nation's university ...
... is a national reference laboratory and a ... development. ARUP offers an extensive test menu ... in clinical and anatomic pathology. Owned by ... include more than half of the nation's ...
... is a national reference laboratory and a ... development. ARUP offers an extensive test menu ... in clinical and anatomic pathology. Owned by ... include more than half of the nation's ...
Medicine Products: